Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Diabetes and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GAD65/GAD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GAD2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active conformation folding. |
View GAD2 Products |
| Gene Delivery | GAD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and antigen presentation assays. |
View GAD2 Products |
| Benchmark Ab | Anti-GAD2 Recombinant Antibody Recombinant positive control for epitope mapping and binding assays. |
View GAD2 Products |
| Validator | GAD2 siRNA Set For knockdown verification in functional GABAergic signaling assays. |
View GAD2 Products |
| Related Target A | GAD1 (GAD67) Subfamily homolog (65% identity) required for off-target counter-screening. |
View GAD1 Products |
| Related Target B | PTPRN (IA-2) Synergistic autoantigen marker in Type 1 Diabetes autoimmune panels. |
View PTPRN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Epitope Preservation | Eukaryotic expression system (HEK293/Insect) ensuring native tertiary folding required for autoantibody recognition. |
| Subfamily Cross-Reactivity (GAD65 vs. GAD67) | High-purity GAD1 and GAD2 proteins available for comparative ELISA and multiplex screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live GAD65/GAD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GAD65 (Glutamate Decarboxylase 2) spans two major medical frontiers: autoimmune disease modulation and neurological disorders. Historically recognized as a premier autoantigen in Type 1 Diabetes (T1D) and Stiff-Person Syndrome (SPS), GAD65 R&D is undergoing a significant transition. Developers are moving away from broad immunosuppression toward antigen-specific immunotherapy (ASIT) and tolerogenic vaccines designed to re-educate the immune system without compromising systemic defense.
The race for GAD65 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antigen-specific tolerogenic therapies, CAR-Treg cells, and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise MHC-class II peptide presentation and combination therapies with immunomodulators like anti-CD3.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Tolerogenic Vaccines / ASIT | Diamyd Medical, Selecta Biosciences | Type 1 Diabetes (LADA), Stiff-Person Syndrome | Conformational antigen integrity (Need high-purity, natively folded GAD2 protein) |
| CAR-Treg / Cell Therapy | Gentibio, Sonoma Biotherapeutics | Autoimmune Neuro-inflammation | T-cell activation and MHC-II peptide presentation assays (Need GAD2 Lentivirus) |
| Gene Therapy / Small Molecules | Asklepios BioPharmaceutical | Parkinson's Disease, Epilepsy | Enzymatic activity preservation assays (Need functionally active GAD2 recombinant protein) |